TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33260253
Drug: Metronidazole benzoate
Normalized name: Metronidazole Benzoate
DrugBank: Metronidazole benzoate (DB15759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole benzoate (25 mg/mL) at 20 mg/kg PO q12h
Study: 33260253
Drug: Metronidazole benzoate
Normalized name: Metronidazole Benzoate
DrugBank: Metronidazole benzoate (DB15759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole benzoate (25 mg/mL) at 10 mg/kg PO q12h
Study: 34420532
Drug: IMPaCT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPaCT therapy
Study: 32461105
Drug: Tucatinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucatinib (300 mg twice daily) in cohort A
Study: 32461105
Drug: Tucatinib (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucatinib (750 mg once daily) in cohort B
Study: 34506972
Drug: Bumetanide treatment
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bumetanide treatment for 91 days
Study: 33686771
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (Er:YAG and Nd:YAG lasers)
Study: 35383908
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (NIVO) plus ipilimumab (IPI) (3 mg/kg + 1 mg/kg every 3 weeks for 4 cycles)
Study: 35383908
Drug: Sunitinib (SUN)
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib (SUN) (50 mg daily for four 6-week cycles)
Study: 33934704
Drug: n‐3 LCPUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 LCPUFA (1 g/day, 694 mg DHA and 397 mg EPA)
Study: 32498226
Drug: Nonconsumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonconsumption of whole grains daily association with T2DM
Study: 35940465
Drug: Oral Itrifal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Itrifal Hakim Ali (IHA) (10g/day) and topical Habb‐e‐Kalaf (HK)
Study: 35940465
Drug: Oral Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Itraconazole (100 mg/day) and local Terbinafine (1%)
Study: 36427054
Drug: Sequential dual-task
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential dual-task measures of listening effort with varying signal-to-noise ratios (SNR)
Study: 35020250
Drug: Restylane (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restylane (Group A) - Superficial injection (Group A1)
Study: 35020250
Drug: Restylane (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restylane (Group A) - Deep injection (Group A2)
Study: 35020250
Drug: Yishumei (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yishumei (Group B) - Superficial injection (Group B1)
Study: 35020250
Drug: Yishumei (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yishumei (Group B) - Deep injection (Group B2)
Study: 36198322
Drug: Deep learning-based
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep learning-based VMAT forward dose calculations using a convolutional neural network trained on dose of individual multi-leaf-collimator VMAT segments.
Study: 36198322
Drug: Deep learning-based
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep learning-based VMAT forward dose calculations on previously unseen IMRT patients.
Study: 33518152
Drug: Dietary arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary arsenic supplementation (0.95, 20.78, 40.67, and 60.25 mg/kg)
Study: 36484428
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg for 13 weeks
Study: 34726329
Drug: HM15136 (10-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM15136 (10-120 μg/kg)
Study: 34726329
Drug: HM15136 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM15136 (80 μg/kg)
Study: 34726329
Drug: HM15136 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM15136 (50 μg/kg or higher)
Study: 32301204
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (1,000 mg/day)
Study: 32012409
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin only (Group-A)
Study: 32012409
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tadalafil with tamsulosin (Group-B)
Study: 34709770
Drug: Type-1 collagen
Normalized name: WHITE SPIRIT TYPE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type-1 collagen cone (CC)
Study: 33186772
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate (UPA) 10 mg per day for 12 weeks
Study: 32317292
Drug: NY‐ESO‐1/ISCOMATRIX vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NY‐ESO‐1/ISCOMATRIX vaccine
Study: 34981548
Drug: Low-intensity, long-wavelength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity, long-wavelength red light therapy (LLRT) (power 0.4 mW, wavelength 635 nm) twice per day for 3 min each session
Study: 32654603
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (n=14)
Study: 33377160
Drug: Lowest tertile
Normalized name: textiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest tertile of baseline serum bicarbonate (23.1 ± 1.6 mmol/L)
Study: 33377160
Drug: Each mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each mmol/L decrease in serum bicarbonate
Study: 32073417
Drug: Intracoronary prourokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary prourokinase administration
Study: 32993574
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy and cetuximab
Study: 34358514
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 3%, 5%, 10%, and 15% Piper guineense oil
Study: 34358514
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 10% and 15% Piper guineense oil
Study: 33400390
Drug: UC-MSC treatment
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSC treatment
Study: 33829271
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg thiamine daily
Study: 33829271
Drug: 2.4 mg
Normalized name: pectin 2.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg thiamine daily
Study: 33829271
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg thiamine daily
Study: 33829271
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg thiamine)
Study: 33849658
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (waiting period)
Study: 32408253
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids (Arginine and Leucine) administered for 10 weeks at a dosage of 0.1 g/kg body mass/day
Study: 38985488
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg aspirin daily
Study: 38985488
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg aspirin daily
Study: 32333512
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser combined with intradermal injection of PRP
Study: 32333512
Drug: Intraderma injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraderma injection of noncross-linked hyaluronic acid
Study: 36165508
Drug: Cilostazol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (50 mg daily, increased to 100 mg/day after 2 weeks)
Study: 33899498
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 5 mg and metoclopramide 10 mg
Study: 33899498
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo (control group)
Study: 32705528
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) therapy for 1 month
Study: 36103251
Drug: Universidade do
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universidade do Bebê (UBB) intervention consisting of monthly workshops focused on reading aloud and a book-lending library
Study: 36028920
Drug: Standardized KS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized KS clinical evaluation tool, palliative care integration, standardized treatment, improved consultative services
Study: 34602640
Drug: Hydromorphone 0.1
Normalized name: HYDROmorphone 0.1 mg/mL-NaCl 0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 0.1 mg/kg BW intramuscularly (IM)
Study: 34602640
Drug: Hydromorphone 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 0.01 mg/kg BW pharmacopuncture at GV20 (GV)
Study: 33184972
Drug: Hypoglossal Neurostimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglossal Neurostimulation therapy (HGNS)
Study: 34078635
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine (EBM) knowledge
Study: 35939102
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 2% lidocaine at the port sites before incision
Study: 34999348
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of recombinant human basic fibroblast growth factor (bFGF) + conventional medication
Study: 33427546
Drug: E6011 400-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 400-mg
Study: 32565444
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (FCM; 15 mg/kg bodyweight)
Study: 33476301
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies to SARS-CoV-2
Study: 32844540
Drug: High dialysate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dialysate magnesium (1.0 mmol/L)
Study: 32844540
Drug: Low dialysate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dialysate magnesium (0.5 mmol/L)
Study: 33319628
Drug: γ‐T‐rich vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: γ‐T‐rich vitamin E mixture (two capsules daily for 7 or 14 days)
Study: 34418014
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol 15mg/Kg administered 15-30 minutes pre-surgery
Study: 34418014
Drug: Fentanyl 2mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2mcg/kg administered at induction of anaesthesia
Study: 35264846
Drug: Inhaled velsecorat
Normalized name: Velsecorat
DrugBank: Velsecorat (DB16347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled velsecorat (1872 µg)
Study: 35264846
Drug: Inhaled velsecorat
Normalized name: Velsecorat
DrugBank: Velsecorat (DB16347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled velsecorat
Study: 32762677
Drug: Integrated EMDR-Dialectical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated EMDR-Dialectical Behavioural Therapy (DBT)
Study: 35841488
Drug: Machined neck
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machined neck implants
Study: 35841488
Drug: Rough neck
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rough neck implants
Study: 32329771
Drug: Elevated progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Elevated progesterone concentrations among women in the lowest quintile of estradiol (<6.30 pg/mL)
Study: 32329771
Drug: Elevated progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Elevated progesterone concentrations among women in higher quintiles of estradiol (Q2‐Q5; ≥6.30 pg/mL)
Study: 33966678
Drug: Lurasidone (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (40, 80, 120, or 160 mg)
Study: 33966678
Drug: Lurasidone (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (combined doses)
Study: 32853709
Drug: 0.1% topical
Normalized name: Halog 0.1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% topical betamethasone valerate cream applied once a day after radiation
Study: 33024992
Drug: Tofacitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (5 mg twice per day for at least 6 months)
Study: 33202066
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 or 2 g)
Study: 35400633
Drug: Edoxaban treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban treatment
Study: 35257962
Drug: Monthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal 2 mg aflibercept (arm 1)
Study: 35257962
Drug: Quarterly intravitreal
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarterly intravitreal 2 mg aflibercept (arm 2)
Study: 36324139
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue 0.025% + conventional therapy (CTx)
Study: 36324139
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue 0.05% + conventional therapy (CTx)
Study: 36324139
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue 0.1% + conventional therapy (CTx)
Study: 36324139
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CTx) alone
Study: 33801019
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation, 745 mg daily for an average of 12.4 years
Study: 32112556
Drug: Integrated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated care intervention (quarterly AF check-ups by trained nurses, monitoring of anticoagulation therapy, consultations from cardiologists)
Study: 35136417
Drug: Manual reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual reduction (treatment group)
Study: 33964855
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg vitamin D3/d
Study: 32638614
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy (HILT) plus routine physical therapy
Study: 32638614
Drug: Sham HILT
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham HILT plus routine physical therapy
Study: 34347950
Drug: REGEN-COV (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGEN-COV (1200 mg subcutaneous injection)
Study: 32568065
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate (starting at 500 mg three times daily, increasing to 1 g three times daily if serum bicarbonate < 22 mmol/l at 3 months)
Study: 32997871
Drug: Cognitive Analytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Analytic Therapy (CAT) plus Treatment as Usual (TAU)
Study: 33522061
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment condition involving toy-based interactions with caregivers.
Study: 35523485
Drug: Epicardial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epicardial injection of hiPSC‐CMs (1×10^8, 2×10^8, and 4×10^8 cells) during CABG surgery
Study: 32471373
Drug: PMES plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMES plus antidepressant
Study: 32471373
Drug: Sham plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham plus antidepressant
Study: 35382961
Drug: Hydromorphone combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone combined with ropivacaine (5 μg/kg hydromorphone + 0.2% ropivacaine)
Study: 32339235
Drug: Hypofractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiation therapy (RT) with concurrent and adjuvant temozolomide (TMZ)
Study: 32339235
Drug: Single modality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single modality treatment with temozolomide (TMZ)
Study: 35920662
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g) and Taniborbactam (0.5 g) administered as a single intravenous infusion over 2 hours.
Study: 32423930
Drug: XZK 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: XZK 1200 mg once per day (OD group)
Study: 32423930
Drug: XZK 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: XZK 600 mg two times per day (TD group)
Study: 34215704
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 200-400 mg/day
Study: 34702123
Drug: Dapagliflozin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin plus standard treatment
Study: 34279564
Drug: Daily coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily coffee intake
Study: 33035457
Drug: Tazemetostat 800
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tazemetostat 800 mg orally twice per day in continuous 28-day cycles
Study: 32853747
Drug: Long-term albumin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term albumin administration
Study: 32853747
Drug: On-treatment serum
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment serum albumin levels
Study: 32853747
Drug: Patients whose
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients whose on-treatment serum albumin remained below normal
Study: 33462580
Drug: Ivermectin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (400 µg/kg for 3 days)
Study: 36037586
Drug: BUP/NX flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP/NX flexible model of care with flexible take-home dosing (n = 138)
Study: 34001462
Drug: Short-course radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiation therapy (SCRT) followed by chemotherapy (FOLFOX ×8 or CAPOX ×5 cycles)
Study: 34001462
Drug: Short-course radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiation therapy (SCRT) followed by chemotherapy
Study: 32736184
Drug: Antidepressant trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant trials
Study: 34037955
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise for 30 min per session, 5 times a week for 6 weeks with conventional treatment
Study: 34037955
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of aerobic exercise plus conventional treatment vs. conventional treatment alone
Study: 35401732
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (in addition to escitalopram oxalate)
Study: 34077745
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone eye drops
Study: 34551229
Drug: Control (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine)
Study: 35799239
Drug: Lactulose monotherapy
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose monotherapy
Study: 35799239
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii monotherapy
Study: 35489037
Drug: 0.3% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% chlorhexidine gluconate vaginal preparation
Study: 34022790
Drug: Three antihypertensive
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three antihypertensive regimens for 6 months
Study: 33559212
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional dorsogluteal injection)
Study: 35902298
Drug: Carryover voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carryover voice therapy using carryover strategies
Study: 35902298
Drug: Traditional voice
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional voice therapy with no emphasis on generalizing process
Study: 35902298
Drug: Carryover voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carryover voice therapy
Study: 35902298
Drug: Controls (eight-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controls (eight-week non-therapy period)
Study: 32751170
Drug: 28 g
Normalized name: SM Syringe 28 g, 0.5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 g of rapeseed protein isolate
Study: 32105268
Drug: Recognan (citicoline),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recognan (citicoline), 100 mg in 1 ml, taken orally for 30 days (daily dosage of 0.5 g).
Study: 32105268
Drug: Comparison group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison group (no medication).
Study: 35990057
Drug: taVNS combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: taVNS combined with electroacupuncture (8 weeks, 3 sessions per week for taVNS; 8 weeks, twice per day for electroacupuncture)
Study: 35990057
Drug: citalopram (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: citalopram (8 weeks, 40 mg/day)
Study: 33861432
Drug: Curcumin supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplement (500 mg daily for 12 weeks)
Study: 32474935
Drug: Platform-switching (PS)
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switching (PS) implants
Study: 32474935
Drug: Platform-matching (PM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-matching (PM) implants